FDA approves teclistamab-cqyv for relapsed or refractory multiple ...
On October 25, 2022, the Food and Drug Administration granted accelerated approval to teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), the first bispecific B-cell maturation antigen...
Bispecific antibodies in the treatment of multiple myeloma
Sep 12, 2024 · Bispecific antibodies are dual antigen targeting constructs that engage the T cells to plasma cells through various target antigens like B-cell membrane antigen (BCMA), G …
Two to Tango: CD3/BCMA Bispecific Antibodies in Multiple …
Oct 20, 2022 · Bispecific antibodies target CD3 present on the surface of T cells and a tumor-specific antigen, in this case BCMA, present on the tumor cells, leading to anticancer activity. …
Bispecific Antibodies for Multiple Myeloma: A Review of …
Various BsAbs targeting MM-specific antigens such as B cell maturation antigen (BCMA), CD38, and CD138 are currently in pre-clinical and clinical development, with promising results. In this …
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 …
Apr 6, 2023 · Here we report the discovery and preclinical characterization of a novel BCMA × CD3 BsAb, WVT078, and initial data from the ongoing phase I dose-escalation study of …
B-cell maturation antigen (BCMA) in multiple myeloma: rationale …
Feb 13, 2020 · Here, we review three common treatment modalities used to target BCMA in the treatment of MM: bispecific antibody constructs, antibody–drug conjugates, and chimeric …
BCMA-Targeted T-Cell–Engager Therapy for Autoimmune Disease
Sep 4, 2024 · In four patients with severe autoimmune disease, teclistimab, a bispecific antibody to B-cell maturation antigen and CD3, resulted in autoantibody reduction and clinical response …
A BCMAxCD3 bispecific T cell–engaging antibody demonstrates …
Mar 2, 2021 · BCMAxCD3 bsAb shows similar antitumor activity compared with BCMA CAR T cells but with different in vivo kinetics. CD3-engaging bispecific antibodies (bsAbs) and …
Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific ...
Jun 2, 2022 · Background: The BCMA × CD3 bispecific antibody teclistamab (tec; JNJ-64007957) redirects CD3+ T cells to mediate T-cell activation and subsequent lysis of BCMA-expressing …
Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor …
This report demonstrated the generation of several antibody designs bivalent, univalent BCMA-CD3 Crossmab KIH; and BCMA-CD3 ScFv KIH with two different CD3 ScFv humanized …